Compare Johnson & Johnson (JNJ) vs State Street PDR S&P Retail ETF (XRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs State Street PDR S&P Retail ETF — how do they compare? Johnson & Johnson trades at $259.62 (market cap $618.09B), while State Street PDR S&P Retail ETF trades at $83.74 (market cap $389.66M). The key difference: Johnson & Johnson is far larger — about 1586.2× State Street PDR S&P Retail ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while State Street PDR S&P Retail ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and State Street PDR S&P Retail ETF for 44 Days on average.
| JNJ | XRT | |
|---|---|---|
Market Cap | $618.09B | $389.66M |
Volume | 6,050,983 | 4,275,820 |
Sector | Health | Broad Market / Factor |
52-Week High | $278.43 | $92.35 |
52-Week Low | $186.00 | $77.28 |
Typical Hold Time | 129 Days | 44 Days |
Enterprise Value | $646.37B | — |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $258.45, up 1.44% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and robust cash flow. Analyst consensus is bullish with a $286.53 price target, though technical indicators show resistance near $260. Recent news highlights pipeline strength including Icotyde's potential $4.5B peak sales.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and competitive pressures. The stock presents value near current levels with 10.7% upside to consensus target, though technical weakness suggests potential near-term consolidation. Long-term growth drivers include oncology portfolio and Ottava surgical system development.
XRT (SPDR S&P Retail ETF) trades at $83.45, up 0.65% with a bullish technical signal despite bearish moving averages. The ETF faces mixed sentiment as retail sales show volatility, with August's 1.2% rebound contrasting July's 0.6% decline. Key resistance sits at $85, while RSI-6 at 84.45 indicates potential overbought conditions. Recent news highlights holiday sales projections exceeding $1 trillion but concerns over consumer spending shifts toward value-oriented purchases.
Outlook remains cautious amid macroeconomic pressures; higher interest rates and inflation weigh on consumer sentiment, with analysts expecting continued underperformance versus broader markets. The ETF's equal-weight approach provides diversification, but selective consumer spending patterns and oil price volatility pose near-term risks. Investment appeal hinges on holiday season performance and Federal Reserve policy direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About State Street PDR S&P Retail ETF
XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →
